The Outsourcing Trap: Why Pharma Needs to Reclaim Manufacturing | Hedley Rees

Has the pharmaceutical industry outsourced its way into a supply chain crisis?

In this episode of Out of the Lab, host Nicholas Crudele sits down with repeat guest Hedley Rees to uncover the systemic risks embedded in the modern pharmaceutical manufacturing model. For decades, the industry has relied on outsourcing to CDMOs and offshoring to lower costs, but this shift has resulted in a devastating loss of internal critical assets and manufacturing capability.

Drawing on powerful analogies—from Apple's tight grip on iPhone manufacturing to Boeing's multi-billion-dollar Dreamliner outsourcing disaster—Hedley explains why pharmaceutical companies must bring clinical and manufacturing expertise back in-house. We also explore the historical success of process-driven drugs like Penicillin, and how current patent laws prioritizing molecule claims over scalable processes are driving massive phase-three failure rates.

In this episode, we cover:

• The Boeing Dreamliner Analogy: The hidden costs and massive delays caused by fragmented supply chains.

• Why CDMOs now own the "critical assets" of drug development, and how that strips product owners of competitive advantage.

• The case for process patents over compound claims to reduce late-stage clinical failures.

• Why early-stage CMC (Chemistry, Manufacturing, and Controls) must be at the center of IP and commercialization strategies.

• The urgent need to reintegrate physicians and engineers directly into the early stages of drug supply chain design.